Medifast, Inc. Research and Development Expense
Medifast, Inc. (MED) reported Research and Development Expense of $4.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-17
- Medifast, Inc. research and development expense for fiscal 2025 was $4.30M, a 6.52% decline from fiscal 2024.
- Medifast, Inc. research and development expense for fiscal 2024 was $4.60M, a 0.00% change from fiscal 2023.
- Medifast, Inc. research and development expense for fiscal 2023 was $4.60M, a 2.22% increase from fiscal 2022.
- Medifast, Inc. research and development expense for fiscal 2022 was $4.50M, a 2.27% increase from fiscal 2021.
| Period end | Research and Development Expense 12 month |
|---|---|
| 2025-12-31 | $4.30M 10-K · filed 2026-02-17 |
| 2024-12-31 | $4.60M 10-K · filed 2026-02-17 |
| 2023-12-31 | $4.60M 10-K · filed 2026-02-17 |
| 2022-12-31 | $4.50M 10-K · filed 2025-02-18 |
| 2021-12-31 | $4.40M 10-K · filed 2024-02-20 |
| 2020-12-31 | $2.80M 10-K · filed 2023-02-21 |
| 2019-12-31 | $2.70M 10-K · filed 2022-02-23 |
| 2018-12-31 | $2.20M 10-K · filed 2021-02-26 |
| 2017-12-31 | $1.50M 10-K · filed 2020-03-02 |
| 2016-12-31 | $2.00M 10-K · filed 2019-03-01 |
| 2015-12-31 | $1.80M 10-K · filed 2018-03-16 |
| 2014-12-31 | $1.30M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COFFEE HOLDING CO INC (JVA) | United States | $0.023B | 4.10 |